Announcement PDF ASX Announcement – 28 September 2023 Annual General Meeting Date and Director Nomination Closing Date In accordance with clause 14.3 of the Company’s Constitution and ASX Listing Rule 3.13.1, Resonance Health Ltd (ASX: RHT) (Company) advises that its next Annual General Meeting (AGM) will be held at 10:00 a.m. (AWST) on Thursday, 16 November 2023. A Notice of Meeting and Explanatory Memorandum containing further particulars of the AGM will be provided to the ASX and security holders in due course. The Closing Date for receipt of nominations for the position of Director is 5 October 2023. Any nominations must be received in writing no later than 5:00pm (AWST) on this date at the Company’s Registered Office. For further information please contact: Mitchell Wells – Non-executive Director & Company Secretary E: mitchellw@resonancehealth.com P: +61 (0)8 9286 5300 This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. About Resonance Health Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development. Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include: § FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment. § FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®. § HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease. Resonance Health Ltd. ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 71, Burswood, WA 6100, AUSTRALIA www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com § HepaFatSmart®, (formerly HepaFat-AI) an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease. § LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFatSmart® into a consolidated report providing accurate assessment of LIC and liver fat. § CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared. The Company has a development pipeline of additional medical imaging analysis products and services, including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis. Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter. Page 2